Last updated on June 2018

Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment

Brief description of study

The primary objectives of this study are to evaluate the effect of Obeticholic Acid treatment compared to placebo on 1) histological improvement and 2) liver-related clinical outcomes in patients with non-cirrhotic nonalcoholic steatohepatitis (NASH) with liver fibrosis.

Clinical Study Identifier: NCT02548351

Contact Investigators or Research Sites near you

Start Over

Robert Falcone, MD

Amici Clinical Research
Martinsville, NJ United States
  Connect »